Clinical meta-analyses of targeted therapies in adenocarcinoma

Addition of vandetanib to chemotherapy in advanced solid cancers

(2012) Xiaomin Wu et al.   ANTI-CANCER DRUGS

Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials

(2012) Yong-Ying Xiao et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Vandetanib Versus Placebo in Patients With Advanced Non–Small-Cell Lung Cancer After Prior Therapy With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor: A Randomized, Double-Blind Phase III Trial (ZEPHYR)

(2012) Jin Soo Lee et al.   JOURNAL OF CLINICAL ONCOLOGY

First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung

(2012) Ji-Youn Han et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

(2012) Rafael Rosell et al.   LANCET ONCOLOGY

Effect of Angiogenesis Inhibitor Bevacizumab on Survival in Patients with Cancer: A Meta-Analysis of the Published Literature

(2012) Yuan Su et al.   PLoS One

Outcome of advanced NSCLC patients harboring sensitizing EGFR mutations randomized to EGFR tyrosine kinase inhibitors or chemotherapy as first-line treatment: a meta-analysis

(2011) E. Bria et al.   ANNALS OF ONCOLOGY

Erlotinib as maintenance therapy in patients with advanced non-small cell lung cancer

(2011) Fausto Petrelli et al.   ANTI-CANCER DRUGS

Gefitinib Compared with Systemic Chemotherapy as First-line Treatment for Chemotherapy-naive Patients with Advanced Non-small Cell Lung Cancer: A Meta-analysis of Randomised Controlled Trials

(2011) F. Wang et al.   CLINICAL ONCOLOGY

Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta-analysis from six phase III randomized controlled trials

(2011) Guanghui Gao et al.   INTERNATIONAL JOURNAL OF CANCER

Vandetanib Plus Pemetrexed for the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Randomized, Double-Blind Phase III Trial

(2011) Richard H. de Boer et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase II Study of Pemetrexed, Carboplatin, and Thoracic Radiation With or Without Cetuximab in Patients With Locally Advanced Unresectable Non–Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 30407

(2011) Ramaswamy Govindan et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Trial of Vandetanib Compared With Erlotinib in Patients With Previously Treated Advanced Non–Small-Cell Lung Cancer

(2011) Ronald B. Natale et al.   JOURNAL OF CLINICAL ONCOLOGY

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

The Role of Vandetanib in the Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Four Randomized Controlled Trials

(2011) Wei-Xiang Qi et al.   LUNG

Cetuximab-based Therapy is Effective in Chemotherapy-naïve Patients with Advanced and Metastatic Non-small-cell Lung Cancer: A Meta-analysis of Randomized Controlled Trials

(2011) Ezzeldin M. Ibrahim et al.   LUNG

Gefitinib vs. chemotherapy as first-line therapy in advanced non-small cell lung cancer: Meta-analysis of phase III trials

(2011) Geoffrey Y. Ku et al.   LUNG CANCER

Efficacy of bevacizumab (Bev) plus chemotherapy (CT) compared to CT alone in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC): Systematic review and meta-analysis

(2011) Tobias Engel Ayer Botrel et al.   LUNG CANCER

Addition of Bevacizumab to Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

(2011) André Bacellar Costa Lima et al.   PLoS One

Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials

(2010) Jingwei Jiang et al.   ACTA ONCOLOGICA

Frontline gefitinib in advanced non-small cell lung cancer: Meta-analysis of published randomized trials

(2010) EzzeldinM Ibrahim   Annals of Thoracic Medicine

Randomized Phase III Trial of Gefitinib versus Docetaxel in Non-Small Cell Lung Cancer Patients Who Have Previously Received Platinum-Based Chemotherapy

(2010) D. H. Lee et al.   CLINICAL CANCER RESEARCH

Effectiveness and Safety of Bevacizumab for Unresectable Non-Small-Cell Lung Cancer

(2010) Kun Yang et al.   CLINICAL DRUG INVESTIGATION

Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis

(2010) Luis Paz-Ares et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Cetuximab and First-Line Taxane/Carboplatin Chemotherapy in Advanced Non–Small-Cell Lung Cancer: Results of the Randomized Multicenter Phase III Trial BMS099

(2010) Thomas J. Lynch et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study of Carboplatin and Paclitaxel Alone or With Sorafenib in Advanced Non–Small-Cell Lung Cancer

(2010) Giorgio Scagliotti et al.   JOURNAL OF CLINICAL ONCOLOGY

Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial

(2010) Roy S Herbst et al.   LANCET ONCOLOGY

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study

(2010) Federico Cappuzzo et al.   LANCET ONCOLOGY

Chemotherapy with cetuximab or chemotherapy alone for untreated advanced non-small-cell lung cancer: A systematic review and meta-analysis

(2010) Hao Lin et al.   LUNG CANCER

Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR

(2010) Makoto Maemondo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cetuximab-based therapy versus non-cetuximab therapy for advanced cancer: a meta-analysis of 17 randomized controlled trials

(2009) Lidan Liu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Somatic EGFR Mutation and Gene Copy Gain as Predictive Biomarkers for Response to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer

(2009) I. J. Dahabreh et al.   CLINICAL CANCER RESEARCH

Epidermal growth factor receptor genomic variation in NSCLC patients receiving tyrosine kinase inhibitor therapy: a systematic review and meta-analysis

(2009) Josh John Carlson et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non–Small-Cell Lung Cancer: AVAiL

(2009) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Vandetanib Versus Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Two-Part, Double-Blind, Randomized Phase II Study

(2009) Ronald B. Natale et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized Phase III Trial of Platinum-Doublet Chemotherapy Followed by Gefitinib Compared With Continued Platinum-Doublet Chemotherapy in Japanese Patients With Advanced Non–Small-Cell Lung Cancer: Results of a West Japan Thoracic Oncology Group Trial (WJTOG0203)

(2009) Koji Takeda et al.   JOURNAL OF CLINICAL ONCOLOGY

Randomized, Double-Blind Trial of Carboplatin and Paclitaxel With Either Daily Oral Cediranib or Placebo in Advanced Non–Small-Cell Lung Cancer: NCIC Clinical Trials Group BR24 Study

(2009) Glenwood D. Goss et al.   JOURNAL OF CLINICAL ONCOLOGY

Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial

(2009) Robert Pirker et al.   LANCET

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: A meta-analysis of 22 studies

(2009) Chen Mao et al.   LUNG CANCER

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

(2009) Rafael Rosell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

The predictive value of epidermal growth factor receptor tests in patients with pulmonary adenocarcinoma: review of current “best evidence” with meta-analysis

(2008) Ruta Gupta et al.   HUMAN PATHOLOGY

Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer

(2008) John V. Heymach et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase III Study, V-15-32, of Gefitinib Versus Docetaxel in Previously Treated Japanese Patients With Non–Small-Cell Lung Cancer

(2008) Riichiroh Maruyama et al.   JOURNAL OF CLINICAL ONCOLOGY

Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial

(2008) Edward S Kim et al.   LANCET

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

(2008) Helena Linardou et al.   LANCET ONCOLOGY

The safety and efficacy of gefitinib versus platinum-based doublets chemotherapy as the first-line treatment for advanced non-small-cell lung cancer patients in East Asia: A meta-analysis

(2008) Chia-Hsuin Chang et al.   LUNG CANCER

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer

(2007) R. Rosell et al.   ANNALS OF ONCOLOGY